|
|
|
|
|
by woodman
3551 days ago
|
|
Thankfully those who shutdown biological weapons development in the DoD didn't follow the same logic. Purely from a strategic perspective: defense costs much more than offense, it doesn't make sense for a superpower to spend more on offense than defense when their potential adversaries can't afford to defend themselves against low cost attacks. |
|
The median venture capitalist in the valley could outspend the US --- actually, probably the world --- on vulnerability acquisition. But there probably isn't an investor and there may not be a single tech company that outspends the USG on defensive security acquisitions.